Skip to content
2000
image of Inavolisib-based Combination Therapy for the Treatment of PIK3CA-Mutated HR+/HER2- Breast Cancer: An Overview

Abstract

Inavolisib is a selective phosphoinositide 3-kinase alpha (PI3Kα) inhibitor representing the next generation of anticancer drugs for the treatment of PIK3CA-mutated HR+/HER2- breast cancer. The dysregulated PI3K/AKT/mTOR signalling axis is an established mechanism of breast cancer progression and resistance to therapy, emphasizing the need for selective inhibitors that have both improved tolerance and efficacy. Inavolisib exhibits enhanced potency and selectivity for PI3Kα, resulting in superior antitumor activity and lower off-target effects than older generations of PI3K inhibitors. The present review provides a comprehensive discussion on inavolisib, covering its structure, pharmacokinetic properties, mechanism of action, and preclinical efficacy. The antitumor effects of combination strategies are also being highlighted for their potential to overcome endocrine resistance and optimize patient outcomes. Furthermore, it discusses the emerging resistance mechanisms to PI3K inhibition, mitigation of adverse effects, and future directions for inavolisib in personalized oncology. As studies continue to demonstrate its clinical utility, inavolisib exhibits preferential activity against the mutated PI3Kα isoform, thereby enhancing therapeutic specificity for combination therapy.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575418114251210151424
2026-02-24
2026-03-03

  • From This Site

    /content/journals/mrmc/10.2174/0113895575418114251210151424
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Harbeck N. Penault-Llorca F. Cortes J. Gnant M. Houssami N. Poortmans P. Ruddy K. Tsang J. Cardoso F. Breast cancer. Nat. Rev. Dis. Primers 2019 5 1 66 10.1038/s41572‑019‑0111‑2 31548545
    [Google Scholar]
  2. Hulka B.S. Stark A.T. Breast cancer: cause and prevention. Lancet 1995 346 8979 883 887 10.1016/S0140‑6736(95)92713‑1 7564675
    [Google Scholar]
  3. Sharma G. Dave R. Sanadya J. Sharma P. Sharma K.K. Various types and management of breast cancer: An overview. J. Adv. Pharm. Technol. Res. 2010 1 2 109 126 10.4103/2231‑4040.72251 22247839
    [Google Scholar]
  4. Orrantia-Borunda E. Anchondo-Nuñez P. Acuña-Aguilar L.E. Gómez-Valles F.O. Ramírez-Valdespino C.A. Subtypes of breast cancer. In: Breast Cancer; Exon citations: Brisbane 2022 10.36255/exon‑citations‑breast‑cancer‑subtypes
    [Google Scholar]
  5. Voduc K.D. Cheang M.C.U. Tyldesley S. Gelmon K. Nielsen T.O. Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 2010 28 10 1684 1691 10.1200/JCO.2009.24.9284 20194857
    [Google Scholar]
  6. Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020 70 1 7 30 10.3322/caac.21590 31912902
    [Google Scholar]
  7. Dent R. Trudeau M. Pritchard K.I. Hanna W.M. Kahn H.K. Sawka C.A. Lickley L.A. Rawlinson E. Sun P. Narod S.A. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007 13 15 4429 4434 10.1158/1078‑0432.CCR‑06‑3045 17671126
    [Google Scholar]
  8. Blair H.A. Inavolisib: First approval. Drugs 2025 85 2 271 278 10.1007/s40265‑024‑02136‑y 39873916
    [Google Scholar]
  9. Turner N.C. Im, S.A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Sunpaweravong, P.; Musolino, A.; Li, H.; Zhang, Q.; Nowecki, Z.; Leung, R.; Thanopoulou, E.; Shankar, N.; Lei, G.; Stout, T.J.; Hutchinson, K.E.; Schutzman, J.L.; Song, C.; Jhaveri, K.L. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N. Engl. J. Med. 2024 391 17 1584 1596 10.1056/NEJMoa2404625 39476340
    [Google Scholar]
  10. Post B. FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation. 2024 Available from:https://www.roche.com/media/releases/med-cor-2024-10-11
  11. Reinhardt K. Stückrath K. Hartung C. Kaufhold S. Uleer C. Hanf V. Lantzsch T. Peschel S. John J. Pöhler M. Bauer M. Bürrig F.K. Weigert E. Buchmann J. Kantelhardt E.J. Thomssen C. Vetter M. PIK3CA-mutations in breast cancer. Breast Cancer Res. Treat. 2022 196 3 483 493 10.1007/s10549‑022‑06637‑w 36279023
    [Google Scholar]
  12. Jean S. Kiger A.A. Classes of phosphoinositide 3-kinases at a glance. J. Cell Sci. 2014 127 5 923 928 10.1242/jcs.093773 24587488
    [Google Scholar]
  13. Backer J.M. The regulation and function of Class III PI3Ks: Novel roles for Vps34. Biochem. J. 2008 410 1 1 17 10.1042/BJ20071427 18215151
    [Google Scholar]
  14. Yang J. Nie J. Ma X. Wei Y. Peng Y. Wei X. Targeting PI3K in cancer: Mechanisms and advances in clinical trials. Mol. Cancer 2019 18 1 26 10.1186/s12943‑019‑0954‑x 30782187
    [Google Scholar]
  15. Biswas K. Yoshioka K. Asanuma K. Okamoto Y. Takuwa N. Sasaki T. Takuwa Y. Essential role of class II phosphatidylinositol-3-kinase-C2α in sphingosine 1-phosphate receptor-1-mediated signaling and migration in endothelial cells. J. Biol. Chem. 2013 288 4 2325 2339 10.1074/jbc.M112.409656 23192342
    [Google Scholar]
  16. Belli C. Repetto M. Anand S. Porta C. Subbiah V. Curigliano G. The emerging role of PI3K inhibitors for solid tumour treatment and beyond. Br. J. Cancer 2023 128 12 2150 2162 10.1038/s41416‑023‑02221‑1 36914722
    [Google Scholar]
  17. Sharma V.R. Gupta G.K. Sharma A.K. Batra N. Sharma D.K. Joshi A. Sharma A.K. PI3K/Akt/mTOR intracellular pathway and breast cancer: Factors, mechanism and regulation. Curr. Pharm. Des. 2017 23 11 1633 1638 10.2174/1381612823666161116125218 27848885
    [Google Scholar]
  18. Wang X. Ding J. Meng L. PI3K isoform-selective inhibitors: Next-generation targeted cancer therapies. Acta Pharmacol. Sin. 2015 36 10 1170 1176 10.1038/aps.2015.71 26364801
    [Google Scholar]
  19. Huang X. You L. Nepovimova E. Psotka M. Malinak D. Valko M. Sivak L. Korabecny J. Heger Z. Adam V. Wu Q. Kuca K. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK). J. Enzyme Inhib. Med. Chem. 2023 38 1 2237209 10.1080/14756366.2023.2237209 37489050
    [Google Scholar]
  20. Song K.W. Edgar K.A. Hanan E.J. Hafner M. Oeh J. Merchant M. Sampath D. Nannini M.A. Hong R. Phu L. Forrest W.F. Stawiski E. Schmidt S. Endres N. Guan J. Wallin J.J. Cheong J. Plise E.G. Lewis Phillips G.D. Salphati L. Heffron T.P. Olivero A.G. Malek S. Staben S.T. Kirkpatrick D.S. Dey A. Friedman L.S. RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (Inavolisib) efficacy. Cancer Discov. 2022 12 1 204 219 10.1158/2159‑8290.CD‑21‑0072 34544753
    [Google Scholar]
  21. Hanan E.J. Braun M.G. Heald R.A. MacLeod C. Chan C. Clausen S. Edgar K.A. Eigenbrot C. Elliott R. Endres N. Friedman L.S. Gogol E. Gu X.H. Thibodeau R.H. Jackson P.S. Kiefer J.R. Knight J.D. Nannini M. Narukulla R. Pace A. Pang J. Purkey H.E. Salphati L. Sampath D. Schmidt S. Sideris S. Song K. Sujatha-Bhaskar S. Ultsch M. Wallweber H. Xin J. Yeap S. Young A. Zhong Y. Staben S.T. Discovery of GDC-0077 (Inavolisib), a highly selective inhibitor and Degrader of mutant PI3Kα. J. Med. Chem. 2022 65 24 16589 16621 10.1021/acs.jmedchem.2c01422 36455032
    [Google Scholar]
  22. Marohl T. Tan J. Zhou W. Guan J. Carlos S. Xie, S Abstract 5388: Triple-threat: Inavolisib and giredestrant combine with palbociclib to achieve sustained cell cycle arrest in ER-positive breast cancer models. Cancer Res. 2022 82 5388 10.1158/1538‑7445.AM2022‑5388
    [Google Scholar]
  23. Mili A. Birangal S. Giridhar J. Nandakumar K. Lobo R. Identification of phytomolecules as isoform and mutation specific PI3K-α inhibitor for protection against breast cancer using e-pharmacophore modeling and molecular dynamics simulations. BMC Chem. 2024 18 1 241 10.1186/s13065‑024‑01317‑w 39696683
    [Google Scholar]
  24. Arabshomali A. Goswami S. Masurkar P.P. Inavolisib for HR-positive, HER2-negative advanced breast cancer. Am. J. Clin. Oncol. 2025 48 10 496 500 10.1097/COC.0000000000001209 40642892
    [Google Scholar]
  25. Ibraheem A.F. Nguyen R. Gadi V.K. Inavolisib therapy in advanced breast cancer. N. Engl. J. Med. 2025 392 3 310 311 10.1056/NEJMc2415114 39813658
    [Google Scholar]
  26. Angelaud R. Bruetsch T. Gosselin F. Han C. Stutz A. Process for the preparation of benzoxazepin oxazolidinone compounds. US Patent 20240166595A1 2023
    [Google Scholar]
  27. Engelman J.A. Luo J. Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006 7 8 606 619 10.1038/nrg1879 16847462
    [Google Scholar]
  28. Bedard P.L. Jhaveri K.L. Accordino M.K. Cervantes P.A. Gambardella V. Hamilton E. Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. Eur. J. Cancer 2025 221 115397 10.1016/j.ejca.2025.115397
    [Google Scholar]
  29. Salphati L. Pang J. Plise E.G. Cheong J. Braun M.G. Friedman L.S. Hong Thibodeau R. Jaochico A. Johnson R. Liu N. Nannini M. Sampath D. Song K. Hannan E.J. Staben S.T. Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human. Xenobiotica 2024 54 10 808 820 10.1080/00498254.2024.2415103 39387185
    [Google Scholar]
  30. Gough S.M. Flanagan J.J. Teh J. Andreoli M. Rousseau E. Pannone M. Bookbinder M. Willard R. Davenport K. Bortolon E. Cadelina G. Gordon D. Pizzano J. Macaluso J. Soto L. Corradi J. Digianantonio K. Drulyte I. Morgan A. Quinn C. Békés M. Ferraro C. Chen X. Wang G. Dong H. Wang J. Langley D.R. Houston J. Gedrich R. Taylor I.C. Oral estrogen receptor PROTAC Vepdegestrant (ARV-471) Is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical er+ breast cancer models. Clin. Cancer Res. 2024 30 16 3549 3563 10.1158/1078‑0432.CCR‑23‑3465 38819400
    [Google Scholar]
  31. Salphati L. Pang J. Alicke B. Plise E.G. Cheong J. Jaochico A. Olivero A.G. Sampath D. Wong S. Zhang X. Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in human. Xenobiotica 2024 54 2 64 74 10.1080/00498254.2024.2303586 38197324
    [Google Scholar]
  32. Gambardella V. Accordino M.K. Bedard P.L. Cervantes A. Hamilton E. Italiano A. Kalinsky K. Krop I.E. Oliveira M. Saura C. Schmid P. Turner N.C. Varga A. Fernandez-Saranillo A. Jin Y. Royer-Joo S. Peters U. Shankar N. Schutzman J.L. Juric D. Jhaveri K.L. Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374). ESMO Open 2025 10 7 105303 10.1016/j.esmoop.2025.105303 40513140
    [Google Scholar]
  33. Zhang J. Approves Inavolisib combo for PIK3CA-mutated, HR+ breast cancer. Curr. Med. Chem. 2025 Epub ahead of print10.2174/0109298673365863250101070254
    [Google Scholar]
  34. Salphati L. Pang J. Plise E.G. Lee L.B. Olivero A.G. Prior W.W. Sampath D. Wong S. Zhang X. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metab. Dispos. 2012 40 9 1785 1796 10.1124/dmd.112.046052 22696419
    [Google Scholar]
  35. Dexheimer T.S. Davoudi Z. Coussens N.P. Silvers T. Morris J. Takebe N. Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids. SLAS Discov. 2025 32 100222 10.1016/j.slasd.2025.100222
    [Google Scholar]
  36. Yu M. Chen J. Xu Z. Yang B. He Q. Luo P. Yan H. Yang X. Development and safety of PI3K inhibitors in cancer. Arch. Toxicol. 2023 97 3 635 650 10.1007/s00204‑023‑03440‑4 36773078
    [Google Scholar]
  37. Ersahin T. Tuncbag N. Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol. Biosyst. 2015 11 7 1946 1954 10.1039/C5MB00101C 25924008
    [Google Scholar]
  38. Fanucci K. Giordano A. Erick T. Tolaney S.M. Sammons S. Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. ESMO Open 2024 9 12 103997 10.1016/j.esmoop.2024.103997 39674130
    [Google Scholar]
  39. Greenwell I.B. Ip A. Cohen J.B. PI3K inhibitors: Understanding toxicity mechanisms and management. Oncology (Williston Park) 2017 31 11 821 828 29179250
    [Google Scholar]
  40. Alves C.L. Ditzel H.J. Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. Int. J. Mol. Sci. 2023 24 5 4522 10.3390/ijms24054522 36901954
    [Google Scholar]
  41. Bissegger L. Constantin T.A. Keles E. Raguž L. Barlow-Busch I. Orbegozo C. Schaefer T. Borlandelli V. Bohnacker T. Sriramaratnam R. Schäfer A. Gstaiger M. Burke J.E. Borsari C. Wymann M.P. Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling. Chem. Sci. (Camb.) 2024 15 48 20274 20291 10.1039/D4SC05459H 39568927
    [Google Scholar]
  42. Chiru E.D. Sojak L. Landin J. Vetter M. Grašič Kuhar C. Pharmacologic management of HR+/HER2− mBC: A clinically oriented review. Front. Oncol. 2025 15 1596634 10.3389/fonc.2025.1596634 40989687
    [Google Scholar]
  43. Castel P. Toska E. Engelman J.A. Scaltriti M. The present and future of PI3K inhibitors for cancer therapy. Nat. Can. 2021 2 6 587 597 10.1038/s43018‑021‑00218‑4 35118422
    [Google Scholar]
  44. Rodon J. Dienstmann R. Serra V. Tabernero J. Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 2013 10 3 143 153 10.1038/nrclinonc.2013.10 23400000
    [Google Scholar]
  45. Muellner M.K. Uras I.Z. Gapp B.V. Kerzendorfer C. Smida M. Lechtermann H. Craig-Mueller N. Colinge J. Duernberger G. Nijman S.M.B. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat. Chem. Biol. 2011 7 11 787 793 10.1038/nchembio.695 21946274
    [Google Scholar]
  46. Dhillon S. Palbociclib: First global approval. Drugs 2015 75 5 543 551 10.1007/s40265‑015‑0379‑9 25792301
    [Google Scholar]
  47. Turner N.C. Ro J. André F. Loi S. Verma S. Iwata H. Harbeck N. Loibl S. Huang Bartlett C. Zhang K. Giorgetti C. Randolph S. Koehler M. Cristofanilli M. Palbociclib in hormone-receptor–positive advanced breast cancer. N. Engl. J. Med. 2015 373 3 209 219 10.1056/NEJMoa1505270 26030518
    [Google Scholar]
  48. Robertson J.F.R. Bondarenko I.M. Trishkina E. Dvorkin M. Panasci L. Manikhas A. Shparyk Y. Cardona-Huerta S. Cheung K.L. Philco-Salas M.J. Ruiz-Borrego M. Shao Z. Noguchi S. Rowbottom J. Stuart M. Grinsted L.M. Fazal M. Ellis M.J. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016 388 10063 2997 3005 10.1016/S0140‑6736(16)32389‑3 27908454
    [Google Scholar]
  49. Carlson R.W. The history and mechanism of action of fulvestrant. Clin. Breast Cancer 2005 6 S5 S8 10.3816/CBC.2005.s.008 15865849
    [Google Scholar]
  50. Osborne C.K. Wakeling A. Nicholson R.I. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br. J. Cancer 2004 90 S1 S2 S6 10.1038/sj.bjc.6601629 15094757
    [Google Scholar]
  51. Ma S. Cho S. Sahasranaman S. Zhao W. Pang J. Ding X. Dean B. Wang B. Hsu J.Y. Ware J. Salphati L. Absorption, metabolism, and excretion of Taselisib (GDC-0032), a potent β-Sparing PI3K inhibitor in rats, dogs, and humans. Drug Metab. Dispos. 2023 51 4 436 450 10.1124/dmd.122.001096 36623882
    [Google Scholar]
  52. Juric D. Kalinsky K. Turner N.C. Jhaveri K.L. Schmid P. Loi S. First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2 negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. J. Clin. Oncol. 2024 42 16 10.1200/JCO.2024.42.16_suppl.1003
    [Google Scholar]
  53. Halder D. Mukherjee S. Jeyaprakash R.S. Exploring target selectivity in designing and identifying PI3Kα inhibitors for triple negative breast cancer with fragment-based and bioisosteric replacement approach. Sci. Rep. 2025 15 1 1890 10.1038/s41598‑024‑83030‑1 39805880
    [Google Scholar]
  54. Sharma P. Kaur M. Khetarpal P. CYP19 gene rs2414096 variant and differential genetic risk of polycystic ovary syndrome: A systematic review and meta-analysis. Gynecol. Endocrinol. 2021 37 2 126 131 10.1080/09513590.2020.1813274 32856958
    [Google Scholar]
  55. Jhaveri K.L. Im, S.A.; Saura, C.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; Shankar, N.; Jin, Y.; Stout, T.J.; Clark, T.D.; Song, C.; Juric, D.; Turner, N.C. Overall survival with Inavolisib in PIK3CA -mutated advanced breast cancer. N. Engl. J. Med. 2025 393 2 151 161 10.1056/NEJMoa2501796 40454641
    [Google Scholar]
  56. To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer. 2021 Available from:https://clinicaltrials.gov/study/NCT03006172
  57. Jhaveri K.L. Accordino M.K. Bedard P.L. Cervantes A. Gambardella V. Hamilton E. Italiano A. Kalinsky K. Krop I.E. Oliveira M. Schmid P. Saura C. Turner N.C. Varga A. Cheeti S. Hilz S. Hutchinson K.E. Jin Y. Royer-Joo S. Peters U. Shankar N. Schutzman J.L. Juric D. Phase I/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer. J. Clin. Oncol. 2024 42 33 3947 3956 10.1200/JCO.24.00110 39236276
    [Google Scholar]
  58. Inman S. Inavolisib delays progression, time to next therapy in PIK3CA-Mutant Breast Cancer. Targeted Oncol. 2024 https://www.targetedonc.com/view/inavolisib-delays-progression-time-to-next-therapy-in-pik3ca-mutant-breast-cancer
    [Google Scholar]
  59. Juric D. Kalinsky K. INAVO121: Phase III study of inavolisib (INAVO)+ fulvestrant (FUL) vs. alpelisib (ALP)+ FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC). J. Clin. Oncol. 2024 42 TPS1136 10.1200/JCO.2024.42.16_suppl.TPS1136
    [Google Scholar]
  60. Swain S. Barrios C. Basho R. Curigliano G. Harbeck N. Huang C-S. Abstract PO2-19-09: INAVO122: a Phase III study of maintenance inavolisib or placebo+ pertuzumab+ trastuzumab following induction with pertuzumab+ trastuzumab+ a taxane in patients with PIK3CA-mutated, HER2-positive advanced breast cancer. Cancer Res. 2024 84 9 10.1158/1538‑7445.SABCS23‑PO2‑19‑09
    [Google Scholar]
  61. Killock D. First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes. Nat. Rev. Clin. Oncol. 2024 1 1 10.1038/s41571‑024‑00968‑x
    [Google Scholar]
  62. Sriravindrarajah A. Hurwitz J. Lim E. Greenfield J.R. Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibition. Endocrinol. Diabetes Metab. Case Rep. 2024 2024 4 24 10.1530/EDM‑24‑0040 39437820
    [Google Scholar]
  63. Froelich W. A triplet drug combination against aggressive breast cancer. 2024 10.1097/01.COT.0001009920.87793.6b
    [Google Scholar]
  64. Balduzzi S. Mantarro S. Guarneri V. Tagliabue L. Pistotti V. Moja L. D’Amico R. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Libr. 2014 2021 2 CD006242 10.1002/14651858.CD006242.pub2 24919460
    [Google Scholar]
  65. Wu H.Y. Chang C.S. Cheng W.H. Chen J.H. Wang Y.H. Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis. Ann. Med. 2025 57 1 2557509 10.1080/07853890.2025.2557509 40922517
    [Google Scholar]
  66. Cho S. Cheruzel L. Cai J. Wrigley S.K. Gemmell R.T. Kokubun T. Steele J.C.P. Salphati L. Zhang D. Khojasteh S.C. Discovery of unprecedented human stercobilin conjugates. Drug Metab. Dispos. 2024 52 9 981 987 10.1124/dmd.124.001725 38991780
    [Google Scholar]
  67. Nunnery S. Mayer I. Management of toxicity to isoform α-specific PI3K inhibitors. Ann. Oncol. 2019 30 21 10.1093/annonc/mdz440
    [Google Scholar]
  68. Roberts M.O.A. Brisco Fields M. Colodonato C. Koirala J. Social determinants of health matter when treating patients with breast cancer. Pharm. Times 2024
    [Google Scholar]
  69. Wedam S. Narayan P. Gittleman H. Cheng J. Bhatnagar V. Sabit H. Price L.S.L. Rahman N.A. Chiu H.J. Biel N. Ricks T. Fiero M. Tang S. Osgood C. Pierce W. Pazdur R. Kluetz P.G. Amiri-Kordestani L. US food and drug administration approval summary: Inavolisib with Palbociclib and Fulvestrant for endocrine-resistant, PIK3CA -mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, locally advanced or metastatic breast cancer. J. Clin. Oncol. 2025 43 28 3123 3131 10.1200/JCO‑25‑00663 40845250
    [Google Scholar]
  70. Dolgin E. Cancer drug approvals and setbacks in 2024. Nat. Cancer 2024 5 12 1756 10.1038/s43018‑024‑00873‑3
    [Google Scholar]
  71. Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006 8 1 E101 E111 10.1208/aapsj080112 16584116
    [Google Scholar]
  72. matta, A.; Sundararajan, R. Analytical quality by design‐based stability‐indicating uhplc method for determination of inavolisib in bulk and formulation. Separ. Sci. Plus 2025 8 8 e70110 10.1002/sscp.70110
    [Google Scholar]
  73. Guengerich F.P. Cytochrome P450 research and The Journal of Biological Chemistry. J. Biol. Chem. 2019 294 5 1671 1680 10.1074/jbc.TM118.004144 29871932
    [Google Scholar]
  74. Liu L. Graff S.L. Wang Y. New emerging therapies targeting PI3K/AKT/mTOR/PTEN pathway in hormonal receptor-positive and HER2-negative breast cancer—current state and molecular pathology perspective. Cancers 2024 17 1 16 10.3390/cancers17010016 39796647
    [Google Scholar]
/content/journals/mrmc/10.2174/0113895575418114251210151424
Loading
Inavolisib-based Combination Therapy for the Treatment of PIK3CA-Mutated HR+/HER2- Breast Cancer: An Overview
Bentham Science Publishers ; https://doi.org/10.2174/0113895575418114251210151424
/content/journals/mrmc/10.2174/0113895575418114251210151424
/content/journals/mrmc/10.2174/0113895575418114251210151424
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: PI3Kα inhibitor ; palbociclib ; pharmacokinetics ; fulvestrant ; Inavolisib ; targeted therapy ; endocrine resistance

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test